Vaxart is focused on developing oral recombinant protein vaccines administered using a convenient room temperature-stable tablet, rather than by injection. Vaxartâs oral vaccines are designed to generate broad and durable immune responses that protect against a wide range of infectious diseases and may be useful for the treatment of chronic viral infections and cancer. The Company is developing prophylactic vaccine candidates that target a range of infectious diseases, including norovirus, a widespread cause of acute gastrointestinal distress for which two Phase 1 human studies have been completed; seasonal influenza, for which a Phase 2 challenge study was recently completed; and respiratory syncytial virus, or RSV, a common cause of respiratory tract infections. In addition, Vaxart is also developing its first therapeutic vaccine targeting cervical cancer and dysplasia caused by HPV types 16 and 18. Source
No articles found.
Amorepacific is Koreaâs No.1 beauty company and a blue-chip corporation. Amorepa...
Amorepacific is Koreaâs No.1 beauty company a...
R1 is a leading provider of revenue cycle services and physician advisory services...
R1 is a leading provider of revenue cycle servi...
Fennec Pharmaceuticals, Inc., (NASDAQ: FENC; TSX: FRX) is a specialty pharmaceutic...
Fennec Pharmaceuticals, Inc., (NASDAQ: FENC; TS...
We are committed to advancing the treatment of eye conditions such as keratoconus ...
We are committed to advancing the treatment of ...
Selecta Biosciences, Inc. is a clinical-stage biotechnology company focused on unl...
Selecta Biosciences, Inc. is a clinical-stage b...
Esperion is a pharmaceutical company passionately committed to developing and comm...
Esperion is a pharmaceutical company passionate...
Sanofi is dedicated to supporting people through their health challenges. We are a...
Sanofi is dedicated to supporting people throug...
Join the National Investor Network and get the latest information with your interests in mind.